These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2832759)

  • 1. Cytomegalovirus immune globulin in renal-transplant recipients.
    N Engl J Med; 1988 Apr; 318(16):1065-7. PubMed ID: 2832759
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients.
    Snydman DR; Werner BG; Heinze-Lacey B; Berardi VP; Tilney NL; Kirkman RL; Milford EL; Cho SI; Bush HL; Levey AS
    N Engl J Med; 1987 Oct; 317(17):1049-54. PubMed ID: 2821397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of cytomegalovirus infection in bone marrow transplant recipients by prophylaxis with an intravenous, hyperimmune cytomegalovirus globulin.
    Condie RM; O'Reilly RJ
    Birth Defects Orig Artic Ser; 1984; 20(1):327-44. PubMed ID: 6329370
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-CMV hyperimmune globulin prophylaxis does not prevent CMV disease in CMV-negative renal transplant patients.
    Pakkala S; Salmela K; Lautenschlager I; Ahonen J; Häyry P
    Transplant Proc; 1992 Feb; 24(1):283-4. PubMed ID: 1311472
    [No Abstract]   [Full Text] [Related]  

  • 5. Review of the efficacy of cytomegalovirus immune globulin in the prophylaxis of CMV disease in renal transplant recipients.
    Snydman DR
    Transplant Proc; 1993 Oct; 25(5 Suppl 4):25-6. PubMed ID: 8212304
    [No Abstract]   [Full Text] [Related]  

  • 6. Cytomegalovirus infection in bone marrow transplant recipients: use of intravenous gamma globulin as a prophylactic and therapeutic agent.
    Kapoor N; Copelan EA; Tutschka PJ
    Transplant Proc; 1989 Feb; 21(1 Pt 3):3095-6. PubMed ID: 2539686
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevention of cytomegalovirus disease in heart transplant recipients by prophylaxis with cytomegalovirus hyperimmune globulin plus oral acyclovir.
    Eisenmann D; Knipp H; Laube H; Stegmann T
    Transplant Proc; 1990 Oct; 22(5):2322-3. PubMed ID: 2171169
    [No Abstract]   [Full Text] [Related]  

  • 8. Final analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus-immune globulin: comparison of the randomized and open-label trials.
    Snydman DR; Werner BG; Tilney NL; Kirkman RL; Milford EL; Cho SI; Bush HL; Levey AS; Strom TB; Carpenter CB
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1357-60. PubMed ID: 1846464
    [No Abstract]   [Full Text] [Related]  

  • 9. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group.
    Falagas ME; Snydman DR; Ruthazer R; Griffith J; Werner BG; Freeman R; Rohrer R
    Clin Transplant; 1997 Oct; 11(5 Pt 1):432-7. PubMed ID: 9361936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus immune globulin.
    Med Lett Drugs Ther; 1988 Oct; 30(777):100. PubMed ID: 2845236
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment of cytomegalovirus infections in renal transplants].
    Rondeau E; Peraldi MN; Kanfer A; Sraer JD
    Nephrologie; 1991; 12(4):189-92. PubMed ID: 1660570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A further analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus immune globulin: interim comparison of a randomized and an open-label trial.
    Snydman DR; Werner BG; Tilney NL; Kirkman RL; Milford EL; Cho SI; Bush HL; Levey AS; Strom TB; Carpenter CB
    Transplant Proc; 1988 Dec; 20(6 Suppl 8):24-30. PubMed ID: 2849222
    [No Abstract]   [Full Text] [Related]  

  • 13. Incidence of infection and acute rejection after cytomegalovirus immune globulin prophylaxis in renal transplantation.
    Basadonna G; Feria A; Perez R; Klein H; Sturges M; Colquhoun S
    Transplant Proc; 1994 Oct; 26(5 Suppl 1):52-3. PubMed ID: 7940976
    [No Abstract]   [Full Text] [Related]  

  • 14. Management of cytomegalovirus infection in high-risk recipients after renal transplantation: prophylaxis by hyperimmunoglobulins or DHPG treatment?
    Tenschert W; Gonnermann D; Meyer-Moldenhauer WH; Cremaschi L; Huland H
    Transplant Proc; 1993 Dec; 25(6):3256-8. PubMed ID: 8266533
    [No Abstract]   [Full Text] [Related]  

  • 15. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis.
    Bonaros N; Mayer B; Schachner T; Laufer G; Kocher A
    Clin Transplant; 2008; 22(1):89-97. PubMed ID: 18217909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of cytomegalovirus disease in transplant recipients.
    Pidgeon GB; Bailey RR
    N Z Med J; 1993 Nov; 106(967):468-9. PubMed ID: 8233192
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients.
    Abate D; Saldan A; Fiscon M; Cofano S; Paciolla A; Furian L; Ekser B; Biasolo MA; Cusinato R; Mengoli C; Bonfante L; Rossi B; Rigotti P; Sgarabotto D; Barzon L; Palù G
    J Infect Dis; 2010 Aug; 202(4):585-94. PubMed ID: 20594105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polyvalent immune globulin and cytomegalovirus infection after renal transplantation.
    Kasiske BL; Heim-Duthoy KL; Tortorice KL; Ney AL; Odland MD; Rao KV
    Arch Intern Med; 1989 Dec; 149(12):2733-6. PubMed ID: 2556978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effective use of cytomegalovirus immune globulin in recipients of orthotopic liver transplants.
    Uber LA
    Am J Hosp Pharm; 1994 Nov; 51(22):2843, 2846. PubMed ID: 7856614
    [No Abstract]   [Full Text] [Related]  

  • 20. Prevention of cytomegalovirus disease in renal allograft recipients.
    Balfour HH
    Scand J Infect Dis Suppl; 1991; 80():88-93. PubMed ID: 1725064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.